Therapeutic Drug Monitoring

The BÜHLMANN Quantum Blue® Therapeutic Drug Monitoring assays are the first rapid tests designed to measure trough levels in a patient’s serum.

This enables prompt dose adjustments before the next treatment.

With results read using a simple bench top reader, this innovative technology provides fast and reliable solutions for therapeutic drug monitoring (TDM) of anti-inflammatory biologics. Offering essential tools for timely and effective management of patient treatments.

Serum Infliximab Quantitative lateral-flow test used with BÜHLMANN Quantum Blue® reader for measuring trough Infliximab levels. Range 0.4-20µg/ml
Serum Infliximab Quantitative lateral-flow test used with BÜHLMANN Quantum Blue® reader for trough Infliximab levels. Range 0.4-20µg/ml. 10 Tests
Serum Adalimumab Quantitative lateral-flow test for BÜHLMANN Quantum Blue reader for measuring trough Adalimumab levels. Range 1.3.35µg/ml
Serum Adalimumab Quantitative lateral-flow test for BÜHLMANN Quantum Blue reader for trough Adalimumab levels. Range 1.3.35µg/ml. 10 Tests
Serum Anti-Infliximab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Infliximab
Serum Anti-Infliximab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Infliximab 10 tests
Serum Anti-Adalimumab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Adalimumab 25 tests
Serum Anti-Adalimumab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Adalimumab 10 tests